Ofatumumab scFv-Transferrin Fusion for Barrier-Crossing Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Many antibodies face challenges in crossing biological barriers such as the blood-brain barrier and blood-eye barrier, and entering cancerous cells, limiting their efficacy and potential applications due to the unnecessary activation of immune responses mediated by the Fc region.
Innovation Solution
A single-chain variable fragment (scFv) is designed to retain antigen-binding properties without the Fc region, conjugated with the N-methyl lobe of transferrin to enhance transcytosis, utilizing transferrin receptor-mediated endocytosis for targeted delivery, and employing environment-sensitive linkers for controlled release within specific cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a whole antibody is used to bind target proteins, then immune effector functions (ADCC, ADCP) are activated, but the antibody cannot efficiently cross biological barriers such as the blood-brain barrier and blood-eye barrier
Solution Approach 1:
The antibody is segmented into its functional components: the scFv region (25-30 kDa) retains antigen-binding capability while the Fc region is removed. This segmentation allows the binding domain to function independently without the size constraints of the full antibody, enabling barrier crossing while maintaining target engagement.
Solution Approach 2:
The Fc region is extracted from the antibody structure, leaving only the scFv region. This extraction eliminates the size barrier (150 kDa → 25-30 kDa) that prevents blood-brain and blood-eye barrier penetration, while preserving the antigen-binding function that provides therapeutic efficacy.
2Length of moving object
If the Fc region is removed to enable barrier crossing, then molecular size is reduced, but immune effector functions are lost
Solution Approach 1:
Transferrin is introduced as an intermediary molecule that binds to the scFv and mediates transcytosis across biological barriers. This intermediary provides the barrier-crossing mechanism that the reduced-size scFv lacks inherently, compensating for the loss of Fc-mediated functions while enabling delivery to target sites.
Solution Approach 2:
The molecular size parameter is changed from 150 kDa (whole antibody) to 25-30 kDa (scFv), which fundamentally alters the transport properties and enables barrier penetration. This parameter change is compensated by introducing transferrin-mediated transcytosis to maintain therapeutic delivery efficacy.
3Length of moving object
If scFv is used instead of whole antibody, then barrier crossing is improved, but circulation time is reduced
Solution Approach 1:
The scFv is merged with transferrin to form a conjugate that combines the barrier-crossing advantage of scFv with the extended circulation properties of transferrin. This merging allows the conjugate to benefit from both the small size of scFv and the long circulation half-life of transferrin.
Solution Approach 2:
The transferrin-conjugated scFv achieves multi-functionality: it maintains the antigen-binding function of scFv, gains the barrier-crossing capability through transferrin receptor interaction, and acquires extended circulation time through transferrin's long half-life, combining benefits from both molecular components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The scFv-conjugate achieves enhanced delivery across biological barriers, reduces off-target effects, and prolongs circulation time, improving therapeutic efficacy and selectivity by ensuring targeted release within target cells.
Implementation Method 1
conjugated with the N-methyl lobe of transferrin to enhance transcytosis, utilizing transferrin receptor-mediated endocytosis for targeted delivery
Implementation Method 2
employing environment-sensitive linkers for controlled release within specific cells
Data Source
AI summary
The efficacy and indication of ofatumumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.